Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Aarhus
With
Pierre Fabre Laboratories
Purpose: In an open-label randomized phase II trial, patients with metastatic Human Epidermal Growth Factor Receptor 2-negative breast cancer with normal organ function sant WHO performance status \< 3 are randomized to receive either capecitabine (day 1-14) plus vinorelbine oral (day 1 and 8) or capecitabine (day 1-14) plus vinorelbine oral metronomic (3 days a week).
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic Human Epidermal Growth Factor Receptor2-Negative breast cancer
WHO performance status \< 3
You may not be if
Former treatment with Capecitabine or Vinorelbine
Patients who have received more than one line of chemotherapy for metastatic disease
Brain metastases
Malabsorption syndrome
Abnormal organ function
pregnant or lactating women
Clareo Health | Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer
